PriceTargets.com logo

XTL Biopharmaceuticals - XTLB Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.69 As of 01/8/2026 10:39 AM ET
▼ -0.444 (-39.29%)
Get New XTL Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XTLB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XTLB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for XTL Biopharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.69.

This chart shows the closing price for XTLB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in XTL Biopharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/8/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/5/2026Weiss RatingsInitiated CoverageSell (E+)
(Data available from 1/8/2021 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/12/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2026

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Read More

Today's Range

Now: $0.69
Low: $1.13
High: $1.13

50 Day Range

MA: $3.99
Low: $3.43
High: $5.20

52 Week Range

Now: $0.69
Low: $0.86
High: $3.05

Volume

N/A

Average Volume

58,190 shs

Market Capitalization

$6.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of XTL Biopharmaceuticals?

The following Wall Street research analysts have issued stock ratings on XTL Biopharmaceuticals in the last year: Weiss Ratings.
View the latest analyst ratings for XTLB.

What is the current price target for XTL Biopharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for XTL Biopharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for XTL Biopharmaceuticals in the next year.
View the latest price targets for XTLB.

What is the current consensus analyst rating for XTL Biopharmaceuticals?

XTL Biopharmaceuticals currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe XTLB will underperform the market and that investors should sell shares of XTL Biopharmaceuticals.
View the latest ratings for XTLB.

What other companies compete with XTL Biopharmaceuticals?

Other companies that are similar to XTL Biopharmaceuticals include Vivos Therapeutics, Finch Therapeutics Group, Scienture, Apollomics and Concord Medical Services. Learn More about companies similar to XTL Biopharmaceuticals.

How do I contact XTL Biopharmaceuticals' investor relations team?

XTL Biopharmaceuticals' physical mailing address is 5 BADNER STREET, RAMAT GAN L3, 4365603. The biopharmaceutical company's listed phone number is (729) 955-7080 and its investor relations email address is [email protected]. The official website for XTL Biopharmaceuticals is www.xtlbio.com. Learn More about contacing XTL Biopharmaceuticals investor relations.